← Leaderboards
Julie E. Johnson
University Of Florida
$637,515
Attributed
$637,515
Total exposure
10
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $209.8K · FY2005–09$250K$187.5K$125K$62.5K$0
'05
'06
'07
'08
'09
Funding mix
By agency
NIH$637,515 · 10
By mechanism
M01$637,515 · 10
Top collaborators
No co-investigators on record.
Most similar at University Of Florida
Same institution · by research overlap
- Julie A. Johnson$37,866,281
- Rhonda M Cooper-Dehoff$672,170
- Alicia M Mohr$4,883,277
- Steven Michael Smith$1,973,717
- Courtney A Miller$16,288,628
Others in their field
Top investigators on “United States National Institutes Of Health”
- Leonard Freedman · Leidos Biomedical Research, Inc.$816,847,401
- Sonia M Thomas · Research Triangle Institute$701,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$642,073,624
- Bambra Strokes · Ppd Development Lp$526,656,217
- Lawrence Corey · Fred Hutchinson Cancer Center$513,687,120
- Tracy L Nolen · Research Triangle Institute$474,487,152
Research focus
United States National Institutes Of HealthInstitutionFundingResearch PersonnelComputer Retrieval Of Information On Scientific Projects DatabaseHypertensionResponseResourcesSourceGrantPharmaceutical PreparationsGenesMetabolicBlood PressureAntihypertensive AgentsClinical TrialsClinical ResearchAtenololMyocardial InfarctionDiureticsLipidsDrug KineticsInsulin SensitivityKidney Failure
Grant awards (11)
CLINICAL TRIAL: PHARMACOGENOMIC EVALUATION OF ANTIHYPERTENSIVE RESPONSES PEAR$61,672
M01 · FY2009 · RR · contact PI
CYP3A5 GENOTYPE: INFLUENCE ON PHARMACOKINETICS, PHARMACODYNAMICS, AND DRUG INTE$9,908
M01 · FY2009 · RR · contact PI
P & P OF FRUCTOSE FOLLOWING SOFT DRINK CONSUMPTION: SUCROSE VS HIGH FRUCTOSE$9,706
M01 · FY2009 · RR · contact PI
ATENOLOL EXPOSURE AS RISK FOR ADVERSE METABOLIC RESPONSES TO BETA BLOCKERS$4,651
M01 · FY2009 · RR · contact PI
CLINICAL TRIAL: PHARMACOGENOMIC EVALUATION OF ANTIHYPERTENSIVE RESPONSES (PEAR)$163,704
M01 · FY2008 · RR · contact PI
CYP3A5 GENOTYPE: INFLUENCE ON PHARMACOKINETICS, PHARMACODYNAMICS, AND DRUG INTS$46,067
M01 · FY2008 · RR · contact PI
PHARMACOGENOMIC EVALUATION OF ANTIHYPERTENSIVE RESPONSES (PEAR)$99,455
M01 · FY2007 · RR · contact PI
CYP3A5 GENOTYPE: INFLUENCE ON PHARMACOKINETICS, PHARMACODYNAMICS, AND DRUG INTS$98,624
M01 · FY2007 · RR · contact PI
CYP3A5 GENOTYPE: INFLUENCE ON PHARMACOKINETICS, PHARMACODYNAMICS, AND DRUG INTS$5,282
M01 · FY2006 · RR · contact PI
BETA-RECEPTOR POLYMORPHISMS AND ANTIHYPERTENSIVE RESPONSE TO BETA-BLOCKERS$8,219
M01 · FY2005 · RR
Beta-receptor polymorphisms and antihypertensive response to beta-blockers$130,227
M01 · FY2004 · RR